

# MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

View Online



[1]

Amori, R.E. et al. 2007. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA*. 298, 2 (Jul. 2007). DOI:<https://doi.org/10.1001/jama.298.2.194>.

[2]

Amy Kennedy 2013. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE*. 8, 3 (2013). DOI:<https://doi.org/doi:10.1371/journal.pone.0058861>.

[3]

Anthony H. Barnett, Jenny Grice 2013. *New Mechanisms in Glucose Control*. BMJ Books; 1 edition.

[4]

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics:  
[http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh\\_082200](http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh_082200).

[5]

Atkinson, M.A. 2012. The Pathogenesis and Natural History of Type 1 Diabetes. *Cold Spring Harbor Perspectives in Medicine*. 2, 11 (Nov. 2012), a007641-a007641. DOI:<https://doi.org/10.1101/cshperspect.a007641>.

[6]

Avery, L. et al. 2012. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care*. 35, 12 (Dec. 2012), 2681–2689. DOI:<https://doi.org/10.2337/dc11-2452>.

[7]

Bailey, C.J. et al. 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet*. 375, 9733 (Jun. 2010), 2223–2233. DOI:[https://doi.org/10.1016/S0140-6736\(10\)60407-2](https://doi.org/10.1016/S0140-6736(10)60407-2).

[8]

Bailey, Stephen Academic Writing : A Handbook for International Students.

[9]

Barry, V.W. et al. 2014. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*. 56, 4 (Jan. 2014), 382–390. DOI:<https://doi.org/10.1016/j.pcad.2013.09.002>.

[10]

Bennett, W.L. et al. 2011. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*. 154, 9 (May 2011). DOI:<https://doi.org/10.7326/0003-4819-154-9-201105030-00336>.

[11]

Bergenstal, R.M. et al. 2010. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*. 363, 4 (Jul. 2010), 311–320. DOI:<https://doi.org/10.1056/NEJMoa1002853>.

[12]

Bethel, M.A. et al. 2017. Assessing the Safety of Sitagliptin in Older Participants in the Trial

Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Care*. 40, 4 (Apr. 2017), 494-501. DOI:<https://doi.org/10.2337/dc16-1135>.

[13]

Beverley M Shields 2015. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open*. 5, 11 (2015). DOI:<https://doi.org/doi:10.1136/bmjopen-2015-009088>.

[14]

Birkeland, K.I. 2015. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*. 3, 10 (Oct. 2015), 752-753. DOI:[https://doi.org/10.1016/S2213-8587\(15\)00282-X](https://doi.org/10.1016/S2213-8587(15)00282-X).

[15]

Brown, J. et al. 1996. Lifestyle interventions for the treatment of women with gestational diabetes. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd.

[16]

Buse, J.B. et al. 2010. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care*. 33, 6 (Jun. 2010), 1255-1261. DOI:<https://doi.org/10.2337/dc09-1914>.

[17]

Buse, J.B. et al. 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet*. 374, 9683 (Jul. 2009), 39-47. DOI:[https://doi.org/10.1016/S0140-6736\(09\)60659-0](https://doi.org/10.1016/S0140-6736(09)60659-0).

[18]

Buse, J.B. et al. 2011. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 154, 2 (Jan. 2011). DOI:<https://doi.org/10.7326/0003-4819-154-2-201101180-00300>.

[19]

Capehorn, M. et al. 2017. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia ). *Diabetic Medicine*. (Mar. 2017). DOI:<https://doi.org/10.1111/dme.13357>.

[20]

Chimen, M. et al. 2012. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*. 55, 3 (Mar. 2012), 542-551. DOI:<https://doi.org/10.1007/s00125-011-2403-2>.

[21]

Choudhary, P. et al. 2012. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*. 29, 7 (Sep. 2012), 280-285. DOI:<https://doi.org/10.1002/pdi.1707>.

[22]

Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>.

[23]

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008: <http://www.nice.org.uk/guidance/ta151>.

[24]

Copeland, K.C. et al. 2013. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS*. 131, 2 (Feb. 2013), 364-382. DOI:<https://doi.org/10.1542/peds.2012-3494>.

[25]

Courtney, H. et al. 2017. Long-term management of type 2 diabetes with glucagon-like

peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. Volume 10, (Mar. 2017), 79–87. DOI:<https://doi.org/10.2147/DMSO.S126763>.

[26]

Creame, P. and Lea, M.R. 2008. *Writing At University: A Guide For Students*. McGraw-Hill Education.

[27]

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013:  
<http://www.nice.org.uk/guidance/ta288>.

[28]

Davies, M. et al. 2017. Introduction of biosimilar insulins in Europe. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1340–1353. DOI:<https://doi.org/10.1111/dme.13400>.

[29]

Davies, M.J. et al. 2008. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*. 336, 7642 (Mar. 2008), 491–495. DOI:<https://doi.org/10.1136/bmj.39474.922025.BE>.

[30]

Dhatariya, K.K. et al. 2017. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1361–1366. DOI:<https://doi.org/10.1111/dme.13427>.

[31]

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3): <https://www.nice.org.uk/guidance/ng3>.

[32]

Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 375, 9733 (Jun. 2010), 2234–2243.  
DOI:[https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0).

[33]

Dungan, K.M. et al. 2014. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*. 384, 9951 (Oct. 2014), 1349–1357.  
DOI:[https://doi.org/10.1016/S0140-6736\(14\)60976-4](https://doi.org/10.1016/S0140-6736(14)60976-4).

[34]

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015: <https://www.nice.org.uk/guidance/ta248>.

[35]

Fagin, J.A. and Wells, S.A. 2016. Biologic and Clinical Perspectives on Thyroid Cancer. *New England Journal of Medicine*. 375, 11 (Sep. 2016), 1054–1067.  
DOI:<https://doi.org/10.1056/NEJMra1501993>.

[36]

Ferrari, M. et al. 2017. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. *Diabetic Medicine*. 34, 11 (Nov. 2017), 1546–1553.  
DOI:<https://doi.org/10.1111/dme.13451>.

[37]

Gale, E.A. 2013. Is type 2 diabetes a category error? *The Lancet*. 381, 9881 (Jun. 2013), 1956–1957. DOI:[https://doi.org/10.1016/S0140-6736\(12\)62207-7](https://doi.org/10.1016/S0140-6736(12)62207-7).

[38]

Gallwitz, B. et al. 2012. 2-year efficacy and safety of linagliptin compared with glimepiride

in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*. 380, 9840 (Aug. 2012), 475–483.  
DOI:[https://doi.org/10.1016/S0140-6736\(12\)60691-6](https://doi.org/10.1016/S0140-6736(12)60691-6).

[39]

Grammes, J. et al. 2017. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine*. (Aug. 2017).  
DOI:<https://doi.org/10.1111/dme.13506>.

[40]

Gray, L.J. et al. 2014. External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice*. 104, 3 (Jun. 2014), 451–458.  
DOI:<https://doi.org/10.1016/j.diabres.2014.03.018>.

[41]

Gray, L.J. et al. 2012. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*. 55, 12 (Dec. 2012), 3238–3244.  
DOI:<https://doi.org/10.1007/s00125-012-2725-8>.

[42]

Green, J.B. et al. 2015. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 373, 3 (Jul. 2015), 232–242.  
DOI:<https://doi.org/10.1056/NEJMoa1501352>.

[43]

Gregg, E.W. 2017. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. *Diabetes Care*. (Aug. 2017).  
DOI:<https://doi.org/10.2337/dci16-0055>.

[44]

Guidelines: <https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>.

[45]

Hadjiconstantinou, M. et al. 2016. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*. 18, 10 (Oct. 2016). DOI:<https://doi.org/10.2196/jmir.5991>.

[46]

Harman-Boehm, I. 2008. Continuous glucose monitoring in type 2 diabetes. *Diabetes Research and Clinical Practice*. 82, (Dec. 2008), S118-S121. DOI:<https://doi.org/10.1016/j.diabres.2008.09.051>.

[47]

Hartman, Y.A.W. et al. 2017. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care*. 40, 9 (Sep. 2017), e120-e121. DOI:<https://doi.org/10.2337/dc17-0787>.

[48]

Heinonen, I. et al. 2013. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*. 3, 6 (May 2013). DOI:<https://doi.org/10.1136/bmjopen-2013-002901>.

[49]

Henson, Joseph 2014. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. (Nov. 2014).

[50]

Hessler, D.M. et al. 2017. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. *Diabetic Medicine*. 34, 9 (Sep. 2017), 1228-1234. DOI:<https://doi.org/10.1111/dme.13381>.

[51]



Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[52]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[53]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[54]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[55]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[56]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[57]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[58]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[59]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[60]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[61]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[62]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[63]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[64]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[65]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[66]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[67]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[68]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[69]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[70]

Inzucchi, S.E. et al. 2015. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 38, 1 (Jan. 2015), 140–149. DOI:<https://doi.org/10.2337/dc14-2441>.

[71]

Jelinek, H.F. et al. 2016. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. *Computers in Biology and Medicine*. 75, (Aug. 2016), 90–97. DOI:<https://doi.org/10.1016/j.compbimed.2016.05.005>.

[72]

John M Jakicic 2005. Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition*. 82, 1 (Jan. 2005), 226S-229S.

[73]

Johnston, B.C. et al. 2014. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*. 312, 9 (Sep. 2014). DOI:<https://doi.org/10.1001/jama.2014.10397>.

[74]

Jones, A.G. and Hattersley, A.T. 2013. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*. 30, 7 (Jul. 2013), 803–817. DOI:<https://doi.org/10.1111/dme.12159>.

[75]

Kamlesh Khunti 2015. Systematic Review and Meta-Analysis of Response Rates and

Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE. 10, 9 (2015). DOI:<https://doi.org/doi:10.1371/journal.pone.0135702>.

[76]

Kenneth Hodson 2010. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine*. 3, 4 (2010). DOI:<https://doi.org/doi:10.1258/om.2010.100025>.

[77]

Latika Sahu 2009. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine*. 2, 4 (2009). DOI:<https://doi.org/doi:10.1258/om.2009.080049>.

[78]

Lee, I.-M. 2010. Physical Activity and Weight Gain Prevention. *JAMA*. 303, 12 (Mar. 2010). DOI:<https://doi.org/10.1001/jama.2010.312>.

[79]

Leelarathna, L. et al. 2017. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1372–1379. DOI:<https://doi.org/10.1111/dme.13412>.

[80]

Leff, D.R. and Heath, D. 2009. Surgery for obesity in adulthood. *BMJ*. 339, sep22 1 (Sep. 2009), b3402–b3402. DOI:<https://doi.org/10.1136/bmj.b3402>.

[81]

Levin, P.A. et al. 2017. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. Volume 10, (Apr. 2017), 123–139. DOI:<https://doi.org/10.2147/DMSO.S130834>.

[82]

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010:  
<https://www.nice.org.uk/guidance/ta203>.

[83]

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010:  
<https://www.nice.org.uk/guidance/ta203>.

[84]

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International  
Federation on Ageing:  
<https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>.

[85]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 375, 4 (Jul. 2016), 311-322.  
DOI:<https://doi.org/10.1056/NEJMoa1603827>.

[86]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 375, 4 (Jul. 2016), 311-322.  
DOI:<https://doi.org/10.1056/NEJMoa1603827>.

[87]

Marso, S.P. et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2  
Diabetes. *New England Journal of Medicine*. (Sep. 2016).  
DOI:<https://doi.org/10.1056/NEJMoa1607141>.

[88]

Medicines adherence: involving patients in decisions about prescribed medicines and  
supporting adherence. CG76, Jan 2009: <https://www.nice.org.uk/guidance/cg76>.

[89]

Merlin C. Thomas 2016. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy*. 7, 3 (2016). DOI:<https://doi.org/doi:10.1007/s13300-016-0189-4>.

[90]

Min, S.H. et al. 2017. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*. 33, 1 (Jan. 2017). DOI:<https://doi.org/10.1002/dmrr.2818>.

[91]

Mishriky, B.M. et al. 2015. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 109, 2 (Aug. 2015), 378–388. DOI:<https://doi.org/10.1016/j.diabres.2015.05.025>.

[92]

Moreno-Castilla, C. et al. 2016. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*. 16, 4 (Apr. 2016). DOI:<https://doi.org/10.1007/s11892-016-0717-7>.

[93]

Narendran, P. et al. 2017. Exercise to preserve  $\beta$ -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. *Diabetic Medicine*. 34, 11 (Nov. 2017), 1521–1531. DOI:<https://doi.org/10.1111/dme.13439>.

[94]

National Obesity Observatory: <http://www.noo.org.uk>.

[95]

Nauck, M. et al. 2014. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*. 37, 8 (Aug. 2014), 2149–2158. DOI:<https://doi.org/10.2337/dc13-2761>.

[96]

Nauck, M.A. et al. 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*. 9, 2 (Mar. 2007), 194–205. DOI:<https://doi.org/10.1111/j.1463-1326.2006.00704.x>.

[97]

Nauck, M.A. and Meier, J.J. 2016. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*. 4, 6 (Jun. 2016), 525–536. DOI:[https://doi.org/10.1016/S2213-8587\(15\)00482-9](https://doi.org/10.1016/S2213-8587(15)00482-9).

[98]

Nissen, S.E. and Wolski, K. 2007. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*. 356, 24 (Jun. 2007), 2457–2471. DOI:<https://doi.org/10.1056/NEJMoa072761>.

[99]

Noctor, E. and Dunne, F. 2015. Postnatal testing following gestational diabetes. *The Lancet Diabetes & Endocrinology*. 3, 10 (Oct. 2015), 761–762. DOI:[https://doi.org/10.1016/S2213-8587\(15\)00322-8](https://doi.org/10.1016/S2213-8587(15)00322-8).

[100]

Nolan, C.J. et al. 2015. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*. 64, 3 (Mar. 2015), 673–686. DOI:<https://doi.org/10.2337/db14-0694>.

[101]

Paul Craddy 2014. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy*. 5, 1 (2014). DOI:<https://doi.org/doi:10.1007/s13300-014-0061-3>.

[102]

Perrin, N.E. et al. 2017. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine*. 34, 11 (Nov. 2017), 1508–1520. DOI:<https://doi.org/10.1111/dme.13448>.

[103]

Persaud, S.J. and Jones, P.M. 2016. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*. 375, 11 (Sep. 2016), 1090–1092. DOI:<https://doi.org/10.1056/NEJMcibr1607950>.

[104]

Pickup, J.C. 2012. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. *New England Journal of Medicine*. 366, 17 (Apr. 2012), 1616–1624. DOI:<https://doi.org/10.1056/NEJMct1113948>.

[105]

Qin, L. et al. 2010. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*. 25, 1 (Jan. 2010), 5–12. DOI:<https://doi.org/10.1007/s10654-009-9395-y>.

[106]

Rasouli, B. et al. 2017. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. *Diabetic Medicine*. 34, 9 (Sep. 2017), 1259–1263. DOI:<https://doi.org/10.1111/dme.13410>.

[107]

Riddle, M.C. et al. 2013. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 36, 9 (Sep. 2013), 2489–2496.



DOI:<https://doi.org/10.2337/dc12-2454>.

[108]

Rinki Murphy 2015. Monogenic diabetes and pregnancy. *Obstetric Medicine*. 8, 3 (2015). DOI:<https://doi.org/doi:10.1177/1753495X15590713>.

[109]

Rizos, C.V. et al. 2016. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*. 90, 8 (Aug. 2016), 1861–1881. DOI:<https://doi.org/10.1007/s00204-016-1737-4>.

[110]

Rotz, M.E. et al. 2015. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*. 69, 5 (May 2015), 531–549. DOI:<https://doi.org/10.1111/ijcp.12572>.

[111]

Ryder, B. et al. 2013. ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes*. 30, 9 (Nov. 2013), 388–391. DOI:<https://doi.org/10.1002/pdi.1816>.

[112]

S M Attard 2015. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. *Nutrition & Diabetes*. 5, 6 (2015). DOI:<https://doi.org/doi:10.1038/nutd.2015.16>.

[113]

Sallis, J.F. et al. 2016. Progress in physical activity over the Olympic quadrennium. *The Lancet*. 388, 10051 (Sep. 2016), 1325–1336. DOI:[https://doi.org/10.1016/S0140-6736\(16\)30581-5](https://doi.org/10.1016/S0140-6736(16)30581-5).

[114]

Samuel, V.T. and Shulman, G.I. 2012. Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. *Cell*. 148, 5 (Mar. 2012), 852–871.  
DOI:<https://doi.org/10.1016/j.cell.2012.02.017>.

[115]

Schauer, P.R. et al. 2017. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 376, 7 (Feb. 2017), 641–651.  
DOI:<https://doi.org/10.1056/NEJMoa1600869>.

[116]

Schauer, P.R. et al. 2017. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 376, 7 (Feb. 2017), 641–651.  
DOI:<https://doi.org/10.1056/NEJMoa1600869>.

[117]

Schauer, P.R. et al. 2012. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 366, 17 (Apr. 2012), 1567–1576.  
DOI:<https://doi.org/10.1056/NEJMoa1200225>.

[118]

Schwartz, S.S. et al. 2016. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the  $\beta$ -Cell-Centric Classification Schema. *Diabetes Care*. 39, 2 (Feb. 2016), 179–186. DOI:<https://doi.org/10.2337/dc15-1585>.

[119]

Sivasubramaniyam, S. et al. 2017. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1456–1460.  
DOI:<https://doi.org/10.1111/dme.13438>.

[120]

Sjöström, L. et al. 2004. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*. 351, 26 (Dec. 2004), 2683–2693. DOI:<https://doi.org/10.1056/NEJMoa035622>.

[121]

Srinivasan, P. et al. 2007. Islet cell transplantation. *Postgraduate Medical Journal*. 83, 978 (Apr. 2007), 224–229. DOI:<https://doi.org/10.1136/pgmj.2006.053447>.

[122]

Steven, S. et al. 2016. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*. 39, 5 (May 2016), 808–815. DOI:<https://doi.org/10.2337/dc15-1942>.

[123]

Steven, S. and Taylor, R. 2015. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*. 32, 9 (Sep. 2015), 1149–1155. DOI:<https://doi.org/10.1111/dme.12722>.

[124]

Stewart, Z.A. et al. 2016. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*. 375, 7 (Aug. 2016), 644–654. DOI:<https://doi.org/10.1056/NEJMoa1602494>.

[125]

Tanner, M. 2016. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*. 165, 4 (Aug. 2016). DOI:<https://doi.org/10.7326/ACPJC-2016-165-4-020>.

[126]

Tao, L. et al. 2015. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine*. 32, 7 (Jul. 2015), 907–919. DOI:<https://doi.org/10.1111/dme.12711>.

[127]

Umpierre, D. 2011. Physical Activity Advice Only or Structured Exercise Training and Association With HbA<sub>1c</sub> Levels in Type 2 Diabetes. *JAMA*. 305, 17 (May 2011). DOI:<https://doi.org/10.1001/jama.2011.576>.

[128]

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care:  
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>.

[129]

Villani, M. et al. 2017. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 34, 9 (Sep. 2017), 1205–1211.  
DOI:<https://doi.org/10.1111/dme.13379>.

[130]

Vloemans, A.F. et al. 2017. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1470–1476. DOI:<https://doi.org/10.1111/dme.13429>.

[131]

Wanner, C. et al. 2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 375, 4 (Jul. 2016), 323–334.  
DOI:<https://doi.org/10.1056/NEJMoa1515920>.

[132]

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan  
Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. *Diabetes Care*.

[133]

Yates, T. and Davies, M.J. 2017. Physical activity and Type 1 diabetes: an underused therapy. *Diabetic Medicine*. 34, 11 (Nov. 2017), 1498–1499.  
DOI:<https://doi.org/10.1111/dme.13445>.

[134]

Yeh, J.S. et al. 2016. Obesity and Management of Weight Loss. *New England Journal of Medicine*. 375, 12 (Sep. 2016), 1187–1189. DOI:<https://doi.org/10.1056/NEJMclde1515935>.

[135]

Young-Hyman, D. et al. 2017. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care*. 40, 2 (Feb. 2017), 287.1-287.  
DOI:<https://doi.org/10.2337/dc17-er02>.

[136]

Zaccardi, F. et al. 2016. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*. 92, 1084 (Feb. 2016), 63–69.  
DOI:<https://doi.org/10.1136/postgradmedj-2015-133281>.

[137]

A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the anglo-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study.

[138]

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE.

[139]

Diagnosis and management of type 1 diabetes in children, young people and adults |  
Guidance and guidelines | NICE.

[140]

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes  
Systematic review and mixed-treatment comparison analysis.

[141]

2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 375, 18 (Nov. 2016), 1799–1802.  
DOI:<https://doi.org/10.1056/NEJMc1611290>.

[142]

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the  
Role for Continuous Glucose Monitoring. *Journal of diabetes science and technology*  
(Online). 3, 4.

[143]

2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 375, 18 (Nov. 2016), 1797–1799. DOI:<https://doi.org/10.1056/NEJMc1611289>.

[144]

2015. Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care*. 38, 8 (Aug. 2015),  
1583–1591. DOI:<https://doi.org/10.2337/dc15-0279>.

[145]

NHS Evidence: an introduction.

[146]

Obesity: identification, assessment and management | Guidance and guidelines | NICE.

[147]

2015. Standards of Medical Care in Diabetes--2015: Summary of Revisions. Diabetes Care. 38, Supplement\_1 (Jan. 2015), S4-S4. DOI:<https://doi.org/10.2337/dc15-S003>.

[148]

2016. The Eatwell Guide. Public Health England.

[149]

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.

[150]

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE.

[151]

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE.